Program Disclosure. Provider is approved by the California Board of Registered Nursing, Provider #13664, for 1.5 contact hours.
|
|
- Caitlin Wilson
- 6 years ago
- Views:
Transcription
1
2 Program Disclosure This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint-sponsorship of the Annenberg Center for Health Sciences at Eisenhower and the Chronic Liver Disease Foundation. The Annenberg Center for Health Sciences at Eisenhower is accredited by the ACCME to provide continuing medical education for physicians. The Annenberg Center for Health Sciences at Eisenhower designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits. Physicians should claim only the credits commensurate with the extent of their participation in the activity. Annenberg Center for Health Sciences is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. A maximum of 1.5 contact hours may be earned for successful completion of this activity. Provider is approved by the California Board of Registered Nursing, Provider #13664, for 1.5 contact hours.
3 Learning Objectives Recognize the clinical trial data, AASLD treatment guidelines and approved product labeling for available therapies. Identify patients who are good candidates for currently available therapy versus those patients that would benefit more from future therapies. Use the knowledge gained to maximize clinical outcomes on a case-by-case basis.
4 Case 1
5 Patient Characteristics (June 2014) 52 year old African American male Chronic hepatitis C (CHC) diagnosed in 2012 History/risk factors BMI=35 Diabetes mellitus Moderate drinker/cigarette smoker
6 Results at Time of Diagnosis (June 2012) Genotype IL28B METAVIR (biopsy) BL viral load 1b TT F2 5,100,000 IU/mL In June 2012, decision was made to wait for future therapies
7 Current Labs (June 2014) Hemoglobin 14.6 g/dl Neutrophils 1,100 cells/mm 3 Platelets 210,000 cells/mm 3 ALT Albumin Bilirubin 84 IU/L 4.0 g/dl 0.7 mg/dl
8 Discussion How would you manage this patient today? Do you require additional information? If so, what? What are the most important factors influencing your decision?
9 What Treatment Options Are Available Now?
10 Boceprevir or Telaprevir + PEG/RBV Approved Regimen for GT 1 (Not advised in AASLD/IDSA Guidance Document)
11 First Direct Acting Antivirals (DAAs) for the Treatment of GT 1 Chronic Hepatitis C Boceprevir and telaprevir were approved in 2011 Both compounds act by inhibiting HCV nonstructural NS3/4A protease Major advancement over PEG/RBV In 2014, use of boceprevir and telaprevir not recommended in AASLD/IDSA guidance document Telaprevir (INCIVEK ) Prescribing Information. Vertex Pharmaceuticals Incorporated, Cambridge, MA. October, Boceprevir (VICTRELIS ) Prescribing Information. Merck Sharp & Dohme Corp., Whitehouse Station, NJ, September 2013.
12 Limitations of Boceprevir and Telaprevir Telaprevir and boceprevir only approved for GT 1 Interferon and ribavirin backbone required Twice per day dosing (BID) for telaprevir and three times per day (TID) dosing for boceprevir Response guided therapy (both) and lead-in (boceprevir) complicated week total treatment duration Limited efficacy in difficult to cure patients (e.g., patients with cirrhosis, prior null responders, African-Americans) Hematologic (both) and rash/dermatological (telaprevir) adverse events Drug-drug interactions Telaprevir (INCIVEK ) Prescribing Information. Vertex Pharmaceuticals Incorporated, Cambridge, MA. October, Boceprevir (VICTRELIS ) Prescribing Information. Merck Sharp & Dohme Corp., Whitehouse Station, NJ, September 2013.
13 Simeprevir/PEG/RBV Approved Regimen for GT 1 with Certain Limitations
14 Simeprevir (SMV) (TMC 435) FDA approval: November 22, 2013 NS3/4A protease inhibitor One capsule taken once daily with food Approved for GT 1 infected subjects with compensated liver disease (including cirrhosis) Alternative therapy according to AASLD/IDSA guidance document Simeprevir (OLYSIO ) Prescribing Information. Janssen Therapeutics, Titusville, NJ. November, 2013.
15 QUEST 1, QUEST 2 and PROMISE Study Designs Response Guided Treatment SMV 150mg/ PEG/RBV* PEG/RBV PEG/RBV Post-Therapy Follow-Up Post-Therapy Follow-Up Placebo/ PEG/RBV PEG/RBV PEG/RBV Post-Therapy Follow-Up Weeks Response Guided Therapy: if HCV RNA <25 IU/mL at Week 4 and undetectable at Week 12, complete treatment at Week 24 QUEST 1 and QUEST 2: GT 1, Treatment Naïve PROMISE: GT 1, Prior Relapsers *PEG/RBV=Peginterferon/Ribavirin
16 SVR12 Rates in Treatment Naive Patients (QUEST 1 and QUEST 2 Combined) 419/ / / / / / 83 49/ 84 23/ / / 133 *Observed prevalence of Q80K variants at baseline in US population in the Phase 2b/3 trials: 48% of GT 1a and 0% of GT 1b patients Simeprevir (OLYSIO ) Prescribing Information. Janssen Therapeutics, Titusville, NJ. November, 2013.
17 Mean values (µmol/l) Mean values (µmol/l) Simeprevir is Well Tolerated Bilirubin Hemoglobin SMV/PR Placebo/PR SMV/PR Placebo/PR Weeks Weeks Mild unconjugated hyperbilirubinemia transporter No anemia signal beyond PEG/RBV Rash up to 25% (mild) Manns M, et al. EASL Abst
18 Adverse Reactions (All Grades): 3% Higher Frequency Among Subjects Receiving SMV/PEG/RBV vs Placebo/PEG/RBV* Preferred Term or Grouped Term SMV/PEG/RBV (First 12 Weeks) N=781 Placebo/PEG/RBV (First 12 Weeks) N=397 Rash (including photosensitivity)** 28% 20% Pruritus 22% 15% Nausea 22% 18% Myalgia 16% 13% Dyspnea 12% 8% *During the first 12 weeks of treatment (pooled phase 3 trials) **Grouped term rash includes 26 preferred terms Simeprevir (OLYSIO ) Prescribing Information. Janssen Therapeutics, Titusville, NJ. November, 2013.
19 Other Important Points SMV + PEG/RBV approved regimen for GT 1 patients; however, Q80K polymorphism testing of GT 1a patients is strongly recommended SMV primarily metabolized by the liver In a Phase 1 study, higher SMV concentrations observed in patients with severe hepatic impairment No SMV dose recommendations given in label
20 Sofosbuvir/PEG/RBV Approved Regimen for GT 1
21 Sofosbuvir (SOF) (GS-7977) FDA approval: December 6, 2013 Nucleotide analog NS5B polymerase inhibitor One oral 400 mg tablet once daily with or without food Approved for GT 1, 2, 3 and 4 Sofosbuvir (SOVALDI ) Prescribing Information. Gilead Sciences, Inc. December, 2013.
22 SVR12 Rates in Treatment-Naïve GT 1 and GT 4 Patients (NEUTRINO) 295/ / / 66 27/ 28 Sofosbuvir (SOVALDI ) Prescribing Information. Gilead Sciences, Inc. December, 2013.
23 SVR Rates in Selected Subgroups (NEUTRINO) 252/ / 54 No Cirrhosis Cirrhosis 47/ / 273 Black Non- Black 37/ 52 *Patients with GT 1, METAVIR F3/F4, IL28B non-cc, HCV RNA >800,000 IU/mL (factors traditionally associated with a lower response to interferonbased treatment). Sofosbuvir (SOVALDI ) Prescribing Information. Gilead Sciences, Inc. December, 2013.
24 SVR12 (%) SVR Rates of SOF-Based Regimens Across Genotypes and Among Patients with Multiple Negative Predictive Factors Retrospective multivariate analysis of Phase 2 and 3 SOF data identified 6 negative predictors associated with relapse Prior treatment failure, cirrhosis, IL28B non-cc, HCV RNA 800,000 IU/mL, body weight 75kg, male gender GT 1 GT 2 GT Foster G, EASL, 2014, O / 4 5/ 5 26/ 26 22/ 22 22/ 22 69/ 69 69/ 70 43/ / 78/ 55/ / 65/ 57/ / 18 26/ 33 Number of Negative Predictors 23/ / 6 8/ 15
25 Predictors of Relapse in GT 1 Patients Univariate Factor Odds Ratio p-value Black race Hispanic ethnicity Male Age 50 y Weight 75 kg IL28B non-cc Cirrhosis HCV RNA 800,000 IU/mL Baseline ALT >1.5 x ULN GT 1b Multivariate Factor Odds Ratio p-value Weight 75 kg IL28B non-cc Cirrhosis Foster G, EASL, 2014, O66
26 SOF+RBV: Treatment-Emergent Adverse Events Reported in >5% of Subjects in Any Treatment Arm Adverse Event PBO (12 weeks) N=71 SOF+RBV (12 weeks) N=650 SOF+RBV (24 weeks) N=250 Fatigue 24% 38% 30% Headache 20% 24% 30% Nausea 18% 22% 13% Insomnia 4% 15% 16% Pruritus 8% 11% 27% Anemia 0% 10% 6% Irritability 1% 10% 10% Diarrhea 6% 9% 12% Rash 8% 8% 9% Asthenia 3% 6% 21% Myalgia 0% 6% 9% Decreased Appetite 10% 6% 6% Influenza Like Illness 3% 3% 6% SOF/PEG/RBV safety similar to PEG/RBV safety Sofosbuvir (SOVALDI ) Prescribing Information. Gilead Sciences, Inc. December, 2013.
27 Other Important Points SOF metabolized by the kidney Renal impairment No dose adjustment is required for patients with mild to moderate renal impairment Safety and efficacy has not been established in patients with severe renal impairment or end stage renal disease No SOF dose adjustment is recommended for patients with mild, moderate and severe hepatic impairment
28 Simeprevir + Sofosbuvir + RBV Investigational Regimen for GT 1 (Included in AASLD/IDSA guidance document)
29 COSMOS Study Design: Randomised, Multicentre, Open-label Trial Week Arm 1 SMV + SOF + RBV Post-treatment follow-up Randomised 2:1:2:1 Arm 2 Arm 3 SMV + SOF + RBV SMV + SOF Post-treatment follow-up Post-treatment follow-up Arm 4 SMV + SOF Post-treatment follow-up SMV 150 mg QD + SOF 400 mg QD ± RBV 1000/1200 mg/day (BID) Cohort 1: METAVIR F0-F2, prior null responders Cohort 2: METAVIR F3-F4, prior null responders or treatment-naïve Stratified by treatment history, HCV GT 1a/1b BID, twice daily; GT, genotype; QD, once daily; RBV, ribavirin; RVR, rapid virologic response; SMV, simeprevir; SOF, sofosbuvir; SVR12, sustained virologic response 12 weeks after end of treatment Lawitz, E. et al. EASL 2014, Abstract #O165
30 Proportion of patients (%) SVR12 in Cohort 2 (F3/F4 Treatment Naïve and Prior Nulls) SVR12 Non-VF Relapse 3% 2/30 2/27 1/14 3/87 2% 2/87 93% 100% 93% 93% 94% 28/30 16/16 25/27 13/14 82/87 SMV/SOF + RBV SMV/SOF SMV/SOF + RBV SMV/SOF SMV/SOF±RBV 24 weeks 12 weeks Overall Is there a need for RBV? Non-VF, Non-virologic failure: patients who did not achieve SVR12 for reasons other than virologic failure Lawitz, E. et al. EASL 2014, Abstract #O165
31 SMV + SOF ± RBV: Adverse Events Patients, n (%) SMV/SOF + RBV (N=30) 24 weeks 12 weeks SMV/SOF (N=16) SMV/SOF + RBV (N=27) SMV/SOF (N=14) Total (N=87) Fatigue 15 (50.0) 6 (37.5) 9 (33.3) 3 (21.4) 33 (37.9) Headache 7 (23.3) 3 (18.8) 5 (18.5) 2 (14.3) 17 (19.5) Nausea 6 (20.0) 3 (18.8) 4 (14.8) 2 (14.3) 15 (17.2) Anemia 7 (23.3) 1 (6.3) 3 (11.1) 0 11 (12.6) Pruritus 5 (16.7) 1 (6.3) 3 (11.1) 2 (14.3) 11 (12.6) Dizziness 4 (13.3) 3 (18.8) 3 (11.1) 1 (7.1) 11 (12.6) Rash 4 (13.3) 0 5 (18.5) 1 (7.1) 10 (11.5) Photosensitivity / sunburn* 2 (6.7) 1 (6.3) 1 (3.7) 1 (7.1) 5 (5.7) *No sun-protective measures were in place for this trial Lawitz, E. et al. EASL 2014, Abstract #O165
32 What Does The Guidance Recommend For Treatment Naïve GT 1 Patients?
33 Guidance Document Language This section assumes that a decision to treat has been made and provides guidance regarding optimal treatment. In many instances, however, it may be advisable to delay treatment for some patients with documented early fibrosis stage (F0-F2), because waiting for future highly effective, pangenotypic, DAA combinations in IFN-free regimens may be prudent. AASLD, IDSA, IAS USA. Recommendations for testing, managing, and treating hepatitis C. Accessed June 13, 2014.
34 Recommended Regimens: GT 1 Treatment Naïve Patients Eligible To Receive IFN SOF + PEG/RBV for 12 weeks Not Eligible To Receive IFN SOF + SMV ± RBV for 12 weeks (not FDA approved) Should be considered ONLY in those patients who require immediate treatment AASLD, IDSA, IAS USA. Recommendations for testing, managing, and treating hepatitis C. Accessed June 13, 2014.
35 Alternative Regimens: GT 1 Treatment Naïve Patients Eligible To Receive IFN SMV + PEG/RBV for 12 weeks followed by PEG/RBV for an additional 12 weeks Only in GT 1b patients GT 1a patients in whom Q80K polymorphism is not detected prior to treatment AASLD, IDSA, IAS USA. Recommendations for testing, managing, and treating hepatitis C. Accessed June 13, 2014.
36 Alternative Regimens: GT 1 Treatment Naïve Patients Not Eligible To Receive IFN SOF + RBV for 24 weeks Preliminary data suggest that this regimen may be less effective than daily SOF plus SMV, particularly among patients with cirrhosis Should be considered ONLY in those patients who require immediate treatment AASLD, IDSA, IAS USA. Recommendations for testing, managing, and treating hepatitis C. Accessed June 13, 2014.
37 Regimens Not Recommended: GT 1 Treatment Naïve Patients PEG/RBV with or without telaprevir or boceprevir for 24 to 48 weeks Monotherapy with PEG, RBV or a DAA AASLD, IDSA, IAS USA. Recommendations for testing, managing, and treating hepatitis C. Accessed June 13, 2014.
38 What About Prior Nonresponders?
39 Case 2
40 Patient History (June 2014) 57 year old Caucasian female CHC diagnosed in 2003 Treated with PEG/RBV in 2004 Non SVR (null responder; <2 log decline in HCV RNA after 12 weeks of therapy) Treated with telaprevir + PEG/RBV in 2012 Non SVR (RVR with breakthrough infection after 7 weeks on therapy)
41 Disease Characteristics/Labs (June 2014) Genotype IL28B METAVIR (biopsy) BL viral load 1a CT F3 2,300,000 IU/mL Hemoglobin 12.6 g/dl Neutrophils 1,300 cells/mm 3 Platelets 150,000 cells/mm 3 ALT 96 IU/L
42 Discussion How would you manage this patient today? Do you require additional information? If so, what? What are the most important factors influencing your decision?
43 What Does The Guidance Document Recommend For GT 1 Previous Nonresponders?
44 Recommended Regimen: GT 1 Previous Nonresponder Patients Previously failed PEG/RBV SOF + SMV ± RBV for 12 weeks Previously failed PEG/RBV + Protease Inhibitor SOF + PEG/RBV for 12 weeks followed by PEG/RBV for up to an additional 12 weeks AASLD, IDSA, IAS USA. Recommendations for testing, managing, and treating hepatitis C. Accessed June 13, 2014.
45 Alternative Regimen: GT 1 Previous PEG/RBV (With or Without Protease Inhibitor) Nonresponder Patients Eligible to Receive IFN SOF + PEG/RBV for 12 weeks followed by PEG/RBV for up to an additional 12 weeks Ineligible to Receive IFN SOF + RBV for 24 weeks AASLD, IDSA, IAS USA. Recommendations for testing, managing, and treating hepatitis C. Accessed June 13, 2014.
46 Alternative Regimen: GT 1 Previous PEG/RBV (Without Protease Inhibitor) Nonresponder Patients Eligible to Receive IFN SMV + PEG/RBV for 12 weeks followed by PEG/RBV for an additional 36 weeks (48 week total duration) AASLD, IDSA, IAS USA. Recommendations for testing, managing, and treating hepatitis C. Accessed June 13, 2014.
47 Regimens Not Recommended: GT 1 Prior Nonresponder Patients PEG/RBV with or without telaprevir or boceprevir Monotherapy with PEG, RBV or a DAA AASLD, IDSA, IAS USA. Recommendations for testing, managing, and treating hepatitis C. Accessed June 13, 2014.
48 Have All Limitations of Boceprevir and Telaprevir Based Therapies Been Addressed By Recently Approved Regimens?
49 Have The Limitations of First Generation DAAs Been Addressed? Interferon and ribavirin backbone required GT 1 and GT 4: PEG/RBV still required GT 2 and GT 3: Interferon-free (SOF+RBV) Twice per day dosing (BID) for telaprevir and three times per day (TID) dosing for boceprevir SOF and SMV both once daily dosing Response guided therapy (RGT) (both) and lead-in (boceprevir) complicated SOF and SMV regimens do not require RGT or lead-in
50 Have The Limitations of First Generation DAAs Been Addressed? Treatment Duration: week treatment GT 1: SOF+PEG/RBV for 12 weeks GT 1: SMV + SOF for 12 weeks GT 1: SMV+PEG/RBV for weeks GT 2: SOF+RBV for 12 weeks GT 3: SOF+RBV for 24 weeks GT 4: SOF+PEG/RBV for 12 weeks
51 Have The Limitations of First Generation DAAs Been Addressed? Limited efficacy in difficult to cure patients (e.g., patients with cirrhosis, prior null responders, African-Americans) GT 1: SMV+PEG/RBV and SOF+PEG/RBV demonstrate improved efficacy in difficult to cure populations GT 2: SOF+RBV strong efficacy GT 3: SOF+RBV less efficacious in null responders with cirrhosis
52 Have The Limitations of First Generation DAAs Been Addressed? Hematologic (both) and rash/dermatological (telaprevir) adverse events No hematologic signal with SMV or SOF monotherapy GT 1: SMV and SOF both require PEG/RBV backbone and hematologic adverse events comparable to PEG/RBV control arm GT 2 and 3: Interferon free regimens have no hematologic signal beyond anemia associated with RBV Drug-drug interactions SMV has DDIs with many of the same drug classes as boceprevir and telaprevir SOF does not have any significant drug:drug interactions
53 General Discussion Q & A
54 A 45-day Follow-up Survey will be sent to your address. Thank you for completing the survey.
55 For more information on the Chronic Liver Disease Foundation (CLDF) and the International Coalition of Hepatology Providers (IC-HEP) please visit Thank You Abbvie and Bristol-Myers Squibb for supporting this program
Program Disclosure. Provider is approved by the California Board of Registered Nursing, Provider #13664, for 1.5 contact hours.
Program Disclosure This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint-sponsorship
More informationHCV Case Study. Treat Now or Wait for New Therapies
HCV Case Study Treat Now or Wait for New Therapies This program is supported by educational grants from Kadmon and Merck Pharmaceuticals. Program Disclosure This activity has been planned and implemented
More informationEmerging Therapies for HCV: Highlights from AASLD 2012 (Part 2)
Emerging Therapies for HCV: Highlights from AASLD 2012 (Part 2) PegIFN and RBV remain vital components of HCV therapy-- selected presentations from: Program Disclosure This activity has been planned and
More informationEmerging Therapies for HCV: Highlights from AASLD 2012 (Part 2)
Emerging Therapies for HCV: Highlights from AASLD 2012 (Part 2) Goals for Hepatitis C Therapy Compared to PegIFN α/rbv, new treatment regimens for chronic hepatitis C should offer: Improved efficacy Efficacy
More informationHIV and Hepatitis C: Advances in Treatment
NORTHWEST AIDS EDUCATION AND TRAINING CENTER HIV and Hepatitis C: Advances in Treatment John Scott, MD, MSc Asst Professor University of Washington Presentation prepared & presented by: John Scott, MD,
More informationEvolution of Therapy in HCV
Hepatitis C: Update on New Therapies and AASLD 13 David Bernstein, MD, FACP, AGAF, FACP Professor of Medicine Hofstra North Shore-LIJ School of Medicine Evolution of Therapy in HCV 199 1999 1 13 (%) SVR
More informationEASL 2013 Interferon Free, All Oral Regimens for Hepatitis C. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain
EASL 2013 Interferon Free, All Oral Regimens for Hepatitis C Maria Buti Hospital Universitario Valle Hebron Barcelona Spain The first Results with Oral therapy: a Protease Inhibitor and NS5A inhibitor
More informationHepatitis C Treatment 2014
Hepatitis C Treatment 214 Brendan M. McGuire, MD UAB Liver Center Outline Epidemiology/National History Terminology for Treatment Treatment Considerations Current Treatment Options Genotype 1 (GT 1) Genotype
More informationUpdate on the Treatment of HCV
Update on the Treatment of HCV K. Rajender Reddy, MD Professor of Medicine Director of Hepatology Director, Viral Hepatitis Center University of Pennsylvania Philadelphia, USA 1 K. Rajender Reddy, MD Disclosure
More informationTreatement Experienced patients without cirrhosis. Rafael Esteban Hospital Universitario Valle Hebron Barcelona
Treatement Experienced patients without cirrhosis Rafael Esteban Hospital Universitario Valle Hebron Barcelona Agenda With IFN PegIFN+ Ribavirin + Simeprevir PegIFN+ Ribavirin+ Sofosbuvir Without IFN Sofosbuvir
More informationSimeprevir + PEG + RBV in Treatment-Naïve Genotype 1 QUEST-1 Trial
Phase 3 Treatment Naïve Simeprevir + in Treatment-Naïve Genotype 1 QUEST-1 Trial Jacobson IM, et al. Lancet. 2014;384:403-13. Simeprevir + PEG + Ribavirin for Treatment-Naïve HCV GT1 QUEST-1 Trial QUEST-1
More informationUpdate in the Management of Hepatitis C: What Does the Future Hold
Update in the Management of Hepatitis C: What Does the Future Hold Paul Y Kwo, MD, FACG Professor of Medicine Mdi Medical ldirector, Liver Transplantation tti Gastroenterology/Hepatology Division Indiana
More information5/12/2016. Learning Objectives. Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients
5/12/216 Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients Alexander Monto, MD Professor of Clinical Medicine University of California San Francisco San Francisco,
More informationCURRENT TREATMENTS. Mitchell L Shiffman, MD Director Liver Institute of Virginia. Richmond and Newport News, VA, USA
CURRENT TREATMENTS FOR HCV Mitchell L Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, VA, USA Liver Institute of Virginia Education, Research and
More informationLatest Treatment Updates for GT 2 and GT 3 Patients
Latest Treatment Updates for GT 2 and GT 3 Patients Eric Lawitz, MD, AGAF, CPI Vice President, Scientific and Research Development The Texas Liver Institute Clinical Professor of Medicine University of
More informationPrior Authorization Guideline
Prior Authorization Guideline Guideline Name Olysio (simeprevir) Formulary UnitedHealthcare Community & State Formulary Note Approval Date 2/19/2014 Revision Date 7/9/2014 1. Indications Drug Name: Olysio
More informationIntroduction. The ELECTRON Trial
63rd AASLD November 9-13, 12 Boston, Massachusetts Faculty Douglas T. Dieterich, MD Professor of Medicine and Director of CME Department of Medicine Director of Outpatient Hepatology Division of Liver
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Hepatitis C First Generation Agents Page 1 of 16 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See also: Hepatitis C First Generation Agents - Through Preferred
More informationTough Cases in HIV/HCV Coinfection
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Tough Cases in HIV/HCV Coinfection John Scott, MD, MSc Assistant Professor University of Washington Presentation prepared by: J Scott Last Updated: Jun 5, 2014
More informationMichael Fried, MD University of North Carolina Chapel Hill, NC. Ira Jacobson, MD Weill Cornell Medical College New York, NY
Nezam Afdhal, MD Beth Israel Deaconess Medical Center Boston, MA Kim Brown, MD Henry Ford Hospital Detroit, MI Michael Fried, MD University of North Carolina Chapel Hill, NC Jordan Feld, MD Toronto Western
More informationCase 4: A 61-year-old man with HCV genotype 3 with cirrhosis. Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA
Case 4: A 61-year-old man with HCV genotype 3 with cirrhosis Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA 1 Genotype 3 case 61-year-old man with HCV genotype 3 Cirrhosis on
More informationSAVINO BRUNO, MD Director Internal Medicine and Hepatology Unit AO Fatebenefratelli e Oftalmico, Milano
SAVINO BRUNO, MD Director Internal Medicine and Hepatology Unit AO Fatebenefratelli e Oftalmico, Milano Market wheretelaprevir has not yet launched Victrelis is still launching January 29 th 214 Developed
More informationHepatitis C: Management of Previous Non-responders with First Line Protease Inhibitors
Hepatitis C: Management of Previous Non-responders with First Line Protease Inhibitors Fred Poordad, MD The Texas Liver Institute Clinical Professor of Medicine University of Texas Health Science Center
More informationTopic: Sovaldi, sofosbuvir Date of Origin: March 14, Committee Approval Date: August 15, 2014 Next Review Date: March 2015
Medication Policy Manual Policy No: dru332 Topic: Sovaldi, sofosbuvir Date of Origin: March 14, 2014 Committee Approval Date: August 15, 2014 Next Review Date: March 2015 Effective Date: October 1, 2014
More informationPivotal New England Journal of Medicine papers 2014 Phase 3 Trial data
4 th HCV Therapy Advances Meeting Paris, December 12-13, 14 Pivotal New England Journal of Medicine papers 14 Phase 3 Trial data Stefan Zeuzem, MD University of Frankfurt Germany Disclosures Consultancies:
More informationUpdate on chronic hepatitis C treatment: current trends, new challenges, what next?
Update on chronic hepatitis C treatment: current trends, new challenges, what next? Matti Maimets 12.06.2015 MMaimets15 Disclosure this presentation is sponsored by Gilead Sciences MMaimets15 MMaimets15
More informationHepatitis C Emerging Treatment Paradigms
Hepatitis C Emerging Treatment Paradigms David R Nelson MD Assistant Vice President for Research Professor of Medicine Director, Clinical and Translational Science Institute University of Florida Gainesville,
More informationPhase 3. Treatment Experienced. Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2. Afdhal N, et al. N Engl J Med. 2014;370:
Phase 3 Treatment Experienced Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2 Afdhal N, et al. N Engl J Med. 2014;370:1483-93. Ledipasvir-Sofosbuvir +/- Ribavirin in Treatment-Experienced HCV
More information2017 UnitedHealthcare Services, Inc.
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 1146-7 Program Prior Authorization/Notification Medication Harvoni (ledipasvir/sofosbuvir) P&T Approval Date 10/2014, 2/2015,
More informationTreatments of Genotype 2, 3,and 4: Now and in the future
Treatments of Genotype 2, 3,and 4: Now and in the future THERAPY FOR THE TREATMENT OF GENOTYPE 2 1 GT 2 and GT 3 Treatment-Naïve: SOF+RBV vs PEG-IFN+RBV FISSION Study Design HCV GT 2 and GT 3 Treatment-naïve
More informationUPDATES IN HEPATITIS C
UPDATES IN HEPATITIS C S A R A H N A I D O O, P H A R M, B C P S AP RI L 13, 2014 OBJECTIVES Be able to discuss changes in hepatitis c treatment Be able to provide recommendations to providers regarding
More informationAgents for the Treatment of Hepatitis C
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document Drugs requiring prior authorization: the list of drugs requiring prior authorization
More informationHow to optimize current therapy for GT1 patients Shortened therapy with IFNa-based therapy
How to optimize current therapy for GT1 patients Shortened therapy with IFNa-based therapy Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Leber- und Studienzentrum
More informationInitial Treatment of HCV G Hugo E. Vargas, MD Professor of Medicine Medical, Director Office of Clinical Research Mayo Clinic Arizona
Initial Treatment of HCV G1 2016 Hugo E. Vargas, MD Professor of Medicine Medical, Director Office of Clinical Research Mayo Clinic Arizona Disclosure Information Disclosure Information Dr. Vargas receives
More informationUpdate on Real-World Experience With HARVONI
Update on Real-World Experience With A RESOURCE FOR PAYERS This information is intended for payers only. The HCV-TARGET and TRIO studies were supported by Gilead Sciences, Inc. Real-world experience data
More informationHepatitis C Emerging Therapy Update: Reports From the Liver Meeting 2012
Reports From the Liver Meeting 212 Project ID: 521 Target Audience This activity has been designed to meet the educational needs of gastroenterologists, hepatologists, physician assistants, and nurse practitioners
More informationLedipasvir-Sofosbuvir (Harvoni)
HEPATITIS WEB STUDY HEPATITIS C ONLINE Ledipasvir-Sofosbuvir (Harvoni) Robert G. Gish MD Professor, Consultant, Stanford University Medical Center Senior Medical Director, St Josephs Hospital and Medical
More informationFuture strategies with new DAAs
Future strategies with new DAAs Ola Weiland professor New direct antiviral drugs Case no 1 male with genotype 2b Male with gt 2b chronic HCV Male with gt 2b relapse afer peg-ifn + RBV during 24 weeks
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Hepatitis C First Generation Agents Page 1 of 18 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See also: Hepatitis C First Generation Agents - Through Preferred
More informationSelecting HCV Treatment
Selecting HCV Treatment Caveats Focus on treatment selection for genotypes 1, 2, and 3. Majority of US population infected with GT 1, 2, or 3 GT 4 treatment closely reflects GT 1 treatment GT 5 and 6 are
More informationTreating HCV Genotype 2 & 3
Treating HCV Genotype 2 & 3 3rd Workshop on HCV Therapy Advances, Rome 14.12.2013 Christoph Sarrazin Klinikum der J. W. Goethe-Universität Frankfurt am Main, Germany HCV Genotypes 2 & 3 Laurel and Hardy
More information47 th Annual Meeting AISF
47 th Annual Meeting AISF Rome, 21 February 2014 Present and future treatment strategies for patients with HCV infection: chronic hepatitis and special populations (HCV/HIV coinfection, advanced cirrhosis,
More informationTreatment of genotype 4 patient. with cirrhosis. Vincent LEROY Clinique Universitaire d Hépato-Gastroentérologie INSERM U823 CHU de Grenoble
Treatment of genotype 4 patient with cirrhosis Vincent LEROY Clinique Universitaire d Hépato-Gastroentérologie INSERM U823 CHU de Grenoble Clinical case 52 year-old patient Intra-venous drug user 1987-1989
More informationAzienda ULSS12 Veneziana
Azienda ULSS12 Veneziana Risultati del trattamento dei monoinfetti con Sofosbuvir, Simeprevir nella coorte veneziana. Confronto di esito con la coorte del trattamento con Boceprevir e Telaprevir Dr.ssa
More informationIFN-free for Genotype 1 HCV: the current landscape. Prof. Graham R Foster
IFN-free for Genotype 1 HCV: the current landscape Prof. Graham R Foster Wonderful new drugs are coming Poordad F, et al. New Engl J Med 2014; online DOI: 10.1056/NEJMoa1402869. 2 The New Drugs Two treatment
More informationClinical Сase A previously relapse to PEG IFN + RBV in HCV G3a patient. Konstantin Zhdanov
Clinical Сase A previously relapse to PEG IFN + RBV in HCV G3a patient Konstantin Zhdanov Genotype 3 in Europe Canada Norway Germany Sweden Czech Republic Poland Approximately 1/3 of HCV-infected patients
More informationClinical Management: Treatment of HCV Mono-infection
Clinical Management: Treatment of HCV Mono-infection Curtis Cooper, MD, FRCPC Associate Professor-University of Ottawa The Ottawa Hospital- Infections Diseases Viral Hepatitis Program- Director Industry
More informationHepatitis C: Management of Treatment Naïve Patients with First Line Protease Inhibitors
Hepatitis C: Management of Treatment Naïve Patients with First Line Protease Inhibitors Eric Lawitz, MD, AGAF, CPI The Texas Liver Institute Clinical Professor of Medicine University of Texas Health Science
More informationICVH 2016 Oral Presentation: 28
Ledipasvir/Sofosbuvir Is Safe and Effective for the Treatment of Patients with Genotype 1 Chronic HCV Infection in Both HCV Mono- and HIV/HCV Coinfected Patients A Luetkemeyer 1, C Cooper 2, P Kwo 3, K
More informationThe HCV Pipeline Ira M. Jacobson, MD, FACP, FACG, AGAF. Slide Presentation. IFN-free DAA combinations (G1)
Slide Presentation The HCV Pipeline Vincent Astor Distinguished Professor of Medicine Chief, Division of Gastroenterology and Hepatology Medical Director, Center for the Study of Hepatitis C Weill Cornell
More informationSECTION 1: OLYSIO with (PEGASYS) AND RIBAVIRIN SECTION 2: OLYSIO with (PEGINTRON) AND RIBAVIRIN RATIONALE FOR INCLUSION IN PA PROGRAM
SECTION 1: OLYSIO with (PEGASYS) AND RIBAVIRIN SECTION 2: OLYSIO with (PEGINTRON) AND RIBAVIRIN RATIONALE FOR INCLUSION IN PA PROGRAM SECTION 1: OLYSIO with (PEGASYS) AND RIBAVIRIN Background Hepatitis
More informationSafety of Treatment in Cirrhotics in the Era of New Antiviral Therapies for Hepatitis C Virus
Safety of Treatment in Cirrhotics in the Era of New Antiviral Therapies for Hepatitis C Virus JEFFREY NADELSON MD, ALAN EPSTEIN MD, THOMAS SEPE MD BOSTON UNIVERSITY SCHOOL OF MEDICINE ROGER WILLIAMS MEDICAL
More informationNovember 2013 AASLD Investor Event 4 November
November 2013 AASLD Investor Event 4 November Maris Hartmanis, President and CEO Charlotte Edenius, EVP Development Bertil Samuelsson, CSA Rein Piir, EVP Corporate Affairs & IR Corporate presentation,
More informationHepatitis C Virus Clinical Criteria Update September 18, For: New York State Medicaid
Hepatitis C Virus Clinical Criteria Update September 18, 2014 For: New York State Medicaid 1 Purpose Characterize the place in therapy for the agents utilized for management of chronic hepatitis C (CHC)
More informationNew developments in HCV research and their implications for front-line practice
New developments in HCV research and their implications for front-line practice Dr. Curtis Cooper Associate Professor, University of Ottawa Director, Ottawa Hospital Viral Hepatitis Program June 17, 2013
More informationTREATMENT OF GENOTYPE 2
Treatment of Genotype 2, 3,and 4 David E. Bernstein, MD, FACG Advisory Committee/Board Member: AbbVie Pharmaceuticals, Gilead, Merck, Janssen Consultant: AbbVie Pharmaceuticals, Bristol-Myers Squibb, Gilead,
More informationTreatment with the New Direct Acting Antivirals for Hepatitis C
Treatment with the New Direct Acting Antivirals for Hepatitis C Mary Olson, DNP, ANP-BC Clinical Trials Program Director Weill Cornell Medical College The Center for the Study of Hepatitis C Objectives
More informationPHARMACY PRIOR AUTHORIZATION Hepatitis C Clinical Guideline
PHARMACY PRIOR AUTHORIZATION Hepatitis C Clinical Guideline Preferred Regimen Based on Diagnosis: Mavyret (glecaprevir/pibrentasvir ) Non-Preferred: Daklinza (daclatasvir) Epclusa (sofosbuvir/velpatasvir)
More informationIFN-free therapy in naïve HCV GT1 patients
IFN-free therapy in naïve HCV GT1 patients Paris Hepatitis Conference Paris, 12th January, 2015 Pr Tarik Asselah MD, PhD; Service d Hépatologie & INSERM U773 University Paris Diderot, Hôpital Beaujon,
More informationRome, February nd Riunione Annuale AISF th AISF ANNUAL MEETING
Rome, February 20-21 nd 2014 Riunione Annuale AISF 2014 14 th AISF ANNUAL MEETING Present and future treatment strategies for patients with HCV infection: chronic hepatitis and special populations IFN
More information2017 Bruce Lucas Hepatology and Liver Transplant Symposium October 13th 2017 Management of Hepatitis C in Pre- and Post-Transplant Patients
2017 Bruce Lucas Hepatology and Liver Transplant Symposium October 13th 2017 Management of Hepatitis C in Pre- and Post-Transplant Patients Jens Rosenau, MD Associate Professor of Medicine Acting Director
More informationHow to optimize treatment in G3 patients? Jérôme GOURNAY, MD Hépatologie Centre Hospitalier Universitaire de Nantes France
How to optimize treatment in G3 patients? Jérôme GOURNAY, MD Hépatologie Centre Hospitalier Universitaire de Nantes France Paris Hepatitis Conference, January 12, 2016 Disclosures I have received funding
More informationDaklinza Sovaldi. Daklinza (daclatasvir) and Sovaldi (sofosbuvir) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Daklinza Sovaldi Page: 1 of 7 Last Review Date: June 24, 2016 Daklinza Sovaldi Description Daklinza
More informationDevelopments in the Treatment of Hepatitis C: A New Era
Developments in the Treatment of Hepatitis C: A New Era Nancy Love, PharmD, BCPS Memorial Medical Center, Johnstown, PA October 17, 2014 Pharmacist Objectives Summarize the results of clinical trials for
More informationAntiviral agents in HCV
Antiviral agents in HCV : Upcoming Therapeutic Options Su Jong Yu, M.D., Ph.D. Department of Internal Medicine, Liver Research Institute, Seoul National University College of Medicine Estimated 170 Million
More informationEASL and The Future of HCV Treatment
EASL and The Future of HCV Treatment Douglas T. Dieterich, M.D Professor of Medicine Division of Liver Diseases, Gastroenterology and Infectious Diseases Department of Medicine Mount Sinai School of Medicine
More informationDirect Acting Antivirals for the Treatment of Hepatitis C Infection
Hepatitis C Core Curriculum, Module 2 Direct Acting Antivirals for the Treatment of Hepatitis C Infection Jason J. Schafer, PharmD, MPH, BCPS, AAHIVP Objectives Discuss the evolution of hepatitis C treatment
More informationHEPATITIS WEB STUDY. Treatment of Hepatitis C following Liver Transplantation
HEPATITIS WEB STUDY Treatment of Hepatitis C following Liver Transplantation Terry D. Box, MD Associate Professor of Medicine Division of Gastroenterology/Hepatology University of Utah Health Sciences
More informationDisclosures 29/09/2014. Genetic determinants of. HCV treatment outcome. IDEAL: IL28B-type is the strongest pre-treatment predictor of SVR
29/9/214 Genetic determinants of ᴧ HCV treatment outcome Disclosures Advisory board member - Gilead, Abbvie, Bristol-Myers Squibb (BMS), Janssen, Merck, and oche Speaker - Gilead, Janssen, Merck, BMS,
More informationHCV In 2015: Maximizing SVR
HCV In 2015: Maximizing SVR Alnoor Ramji Gastroenterology & Hepatology Clinical Associate Professor Division of Gastroenterology University Of British Columbia ramji_a@hotmail.com Disclosures (within Last
More informationHarvoni. Harvoni (ledipasvir & sofosbuvir) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Harvoni Page: 1 of 7 Last Review Date: June 19, 2015 Harvoni Description Harvoni (ledipasvir &
More informationExpert Perspectives: Best of HCV from EASL 2015
Best of HCV from EASL 2015 Expert Perspectives: Best of HCV from EASL 2015 Saeed Hamid, MD Alex Thompson, MD, PhD This activity is supported by educational grants from AbbVie, Bristol-Myers Squibb, and
More informationUpdate on Real-World Experience With HARVONI
Update on Real-World Experience With A RESOURCE FOR PAYERS MAY 217 This information is intended for payers only. The HCV-TARGET study was supported by Gilead Sciences, Inc. Real-world experience data were
More informationHCV Treatment in 2016: Genotypes 1, 2, and 3. Cody A. Chastain, MD October 12, 2016
HCV Treatment in 2016: Genotypes 1, 2, and 3 Cody A. Chastain, MD October 12, 2016 Disclosures I have no financial disclosures. Caveats I will only discuss treatment of GT 1-3. Majority of US population
More informationProtease inhibitor based triple therapy in treatment experienced patients
Protease inhibitor based triple therapy in treatment experienced patients Universitätsklinikum Leipzig Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Leber
More informationOlysio (simeprivir) Policy Number: Last Review: 09/2017 Origination: 09/2013 Next Review: 09/2018
Olysio (simeprivir) Policy Number: 5.01.604 Last Review: 09/2017 Origination: 09/2013 Next Review: 09/2018 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Olysio (simeprivir)
More informationVosevi (sofosbuvir/velpatasvir/voxilaprevir)
Vosevi (sofosbuvir/velpatasvir/voxilaprevir) Policy Number: 5.01.646 Last Review: 10/2017 Origination: 10/2017 Next Review: 11/2018 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide
More informationAntiviral treatment in HCV cirrhotic patients on waiting list
Antiviral treatment in HCV cirrhotic patients on waiting list Krzysztof Tomasiewicz Department of Hepatology and Infectious Diseases Medical University of Lublin, Poland Disclosures Consultancy/Advisory
More informationASSAYS UTILZIED TO MONITOR HCV AND ITS TREATMENT
ASSAYS UTILZIED TO MONITOR HCV AND ITS TREATMENT Mitchell L Shiffman, MD Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, VA Liver Institute of Virginia Education, Research
More informationHepatitis C Agents
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.41 Subject: Hepatitis C Agents Page: 1 of 20 Last Review Date: March 16, 2018 Hepatitis C Agents Description
More informationHepatitis C Agents
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.41 Subject: Hepatitis C Agents Page: 1 of 19 Last Review Date: December 8, 2017 Hepatitis C Agents
More informationGenotype 1 HCV in 2016: Clinical Decision Making in a Time of Plenty
Genotype 1 HCV in 216: Clinical Decision Making in a Time of Plenty Ira M. Jacobson, MD Chair, Department of Medicine Mount Sinai Beth Israel Senior Faculty and Vice-Chair, Department of Medicine Icahn
More informationPEARL-I. Ombitasvir + Paritaprevir + Ritonavir +/- Ribavirin in HCV GT4. Treatment Naïve and Treatment Experienced
Phase 2b Treatment Naïve and Treatment Experienced Ombitasvir + Paritaprevir + Ritonavir +/- Ribavirin in HCV GT4 PEARL-I Hézode C, et al. Lancet. 2015 March 30. [Epub ahead of print] PEARL-I: Study Design
More informationHow do you optimize HCV Treatment for Cirrhotic Patients APASL STC Cebu
How do you optimize HCV Treatment for Cirrhotic Patients APASL STC Cebu Seng Gee Lim Chairman, APASL Liver Week 2013 Professor of Medicine Dept of Gastroenterology and Hepatology NUHS, Singapore Disclosures
More information10/21/2016. Susanna Naggie, MD, MHS Associate Professor of Medicine Duke University Durham, North Carolina. Learning Objectives
A Crash Course on the AASLD/IDSA Hepatitis C Virus Infection Treatment Guidelines: What s New Susanna Naggie, MD, MHS Associate Professor of Medicine Duke University Durham, North Carolina FORMATTED: 1/3/16
More informationGlecaprevir-Pibrentasvir in Cirrhotic Genotype 1, 2, 4, 5, and 6 EXPEDITION-1
Phase 3 Treatment-Naïve and Treatment-Experienced Glecaprevir-Pibrentasvir in Cirrhotic Genotype 1, 2, 4, 5, and 6 EXPEDITION-1 EXPEDITION-1: Study Features EXPEDITION-1 Trial Design: Open-label, single-arm,
More informationDrug Class Monograph
Drug Class Monograph Class: Chronic Hepatitis C Drugs(s): Daclatasvir (Daklinza), Dasabuvir/ombitasivir/paritaprevir/ritonavir (Viekira Pak), Elbasvir/grazoprevir (Zepatier), Peginterferon alfa-2a (Pegasys),
More informationDaklinza Sovaldi. Daklinza (daclatasvir) and Sovaldi (sofosbuvir) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.36 Subject: Daklinza Page: 1 of 8 Last Review Date: March 18, 2016 Daklinza Description Daklinza (daclatasvir)
More informationPHARMACY PRIOR AUTHORIZATION Hepatitis C Clinical Guideline
Preferred Regimen Based on Diagnosis: Mavyret (glecaprevir/pibrentasvir) PHARMACY PRI AUTHIZATION Hepatitis C Clinical Guideline Non-Preferred: Daklinza (daclatasvir) Epclusa (sofosbuvir/velpatasvir) Harvoni
More informationExpress Scripts, Inc. monograph dated 5/25/2011; selected revision 6/1/2011
BENEFIT DESCRIPTION AND LIMITATIONS OF COVERAGE ITEM: PRODUCT LINES: COVERED UNDER: DESCRIPTION: CPT/HCPCS Code: Company Supplying: Setting: Coverage Criteria: Approval Period: Victrelis (boceprevir capsules)
More informationExperience with pre-transplant antiviral treatment: PEG/RBV and DAA. Xavier Forns, MD Liver Unit Hospital Clínic IDIBAPS and CIBREHD Barcelona
Experience with pre-transplant antiviral treatment: PEG/RBV and DAA Xavier Forns, MD Liver Unit Hospital Clínic IDIBAPS and CIBREHD Barcelona Interferon-free regimens G1b nulls Asunaprevir (PI) + Daclatasvir
More informationHarvoni. Harvoni (ledipasvir & sofosbuvir) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.03.32 Subject: Harvoni Page: 1 of 7 Last Review Date: December 3, 2015 Harvoni Description Harvoni (ledipasvir
More informationCENTENE PHARMACY AND THERAPEUTICS DRUG REVIEW 3Q17 July August
BRAND NAME Technivie GENERIC NAME Ombitasvir/paritaprevir/ritonavir MANUFACTURER AbbVie, Inc. DATE OF APPROVAL February 27, 2017 PRODUCT LAUNCH DATE Already available on the market REVIEW TYPE Review type
More informationBristol-Myers Squibb. HCV Full Development Portfolio Overview. Richard Bertz Int Workshop CP HIV Meeting Amsterdam, Netherlands 24 April 2013
Bristol-Myers Squibb HCV Full Development Portfolio Overview Richard Bertz Int Workshop CP HIV Meeting Amsterdam, Netherlands 24 April 2013 1 BMS Agents in Clinical Development: DAAs and INF Lambda Lambda
More information2017 UnitedHealthcare Services, Inc.
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 2052-10 Program Prior Authorization/Medical Necessity Medication Harvoni (ledipasvir/sofosbuvir) P&T Approval Date 4/2015, 8/2015,
More informationDr. Siddharth Srivastava
Dr. Siddharth Srivastava MD, DM (Gastroenterology) Associate Professor GIPMER, New Delhi Rashtriya Gaurav Award 2013 for work on hepatitis B and C Set up Liver clinic at GIPMER and in charge EUS laboratory.
More informationSVR Updates from the 2013 EASL
Updates from the 2013 EASL By Tracy Swan, Treatment Action Group Streamlining HCV Treatment Treatment for hepatitis C virus (HCV) is becoming simpler, shorter, and more effective. All-oral combinations
More informationHarvoni. Harvoni (ledipasvir & sofosbuvir) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.32 Subject: Harvoni Page: 1 of 9 Last Review Date: March 18, 2016 Harvoni Description Harvoni (ledipasvir
More informationClinical Policy: Simeprevir (Olysio) Reference Number: CP.CPA.289 Effective Date: Last Review Date: Line of Business: Commercial
Clinical Policy: (Olysio) Reference Number: CP.CPA.289 Effective Date: 11.01.16 Last Review Date: 08.18 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important
More informationDrug Class Prior Authorization Criteria Hepatitis C
Drug Class Prior Authorization Criteria Hepatitis C Line of Business: Medicaid P & T Approval Date: Interim (pending P&T approval) Effective Date: July 1, 2018 This policy has been developed through review
More information